Literature DB >> 17670004

Comparison of sodium nitroprusside versus esmolol for the treatment of hypertension following repair of coarctation of the aorta.

Sven Dittrich1, Joannis Germanakis, Heike Dittrich, Ingo Daehnert, Peter Ewert, Vladimir Alexi-Meskishvili, Michael Vogel, Peter E Lange.   

Abstract

Postoperative arterial hypertension was treated with nitroprusside or esmolol in a prospective randomized study. If treatment failed, patients were first switched over to the other study drug, and then to a combination of both. Renin, angiotensin II, epinephrine, and norepinephrine were measured before, 1, and 17 h after operation. esmolol was effective in all cases of treatment (n=6) whereas nitroprusside was ineffective in two out of seven patients (not significant), who were finally treated effectively with the combination of the study drugs. Whenever monotherapy failed, both drugs together were effective in reducing the postoperative activation of the sympathetic and renin-angiotensin systems.

Entities:  

Year:  2003        PMID: 17670004     DOI: 10.1016/S1569-9293(02)00115-9

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  3 in total

1.  Use of dexmedetomidine as an adjunct in the treatment of paradoxical hypertension after surgical repair of coarctation of the aorta in infants.

Authors:  Manoj K Sahu; Vinod Kumar Manikala; Sarvesh Pal Singh; A K Bisoi; Ujjwal Kumar Chowdhury
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

2.  Assessment the effect of dexmedetomidine on incidence of paradoxical hypertension after surgical repair of aortic coarctation in pediatric patients.

Authors:  Rabie Soliman; Dalia Saad
Journal:  Ann Card Anaesth       Date:  2018 Jan-Mar

Review 3.  Hypertensive Crisis in Pediatric Patients: An Overview.

Authors:  Rupesh Raina; Zubin Mahajan; Aditya Sharma; Ronith Chakraborty; Sarisha Mahajan; Sidharth K Sethi; Gaurav Kapur; David Kaelber
Journal:  Front Pediatr       Date:  2020-10-20       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.